• Product NameIsavuconazonium sulfate
• Brief DescriptionInhibitors
• Purification96.93%
• Biological ActivityIsavuconazole?(BAL4815; trade name?Cresemba) is a?triazole antifungal?drug. Isavuconazole has been approved by the FDA for treatment of invasive aspergillosis and invasive mucormycosis in adults. Both infections are caused by mold and fungi common to the environment, and occur in individuals who are immunosuppressed or have other complicating conditions, such as diabetes or lung disease
• Target NameOthers
• CAS No. 946075-13-4
• Calculated MW 814.84
• Formulation C35H36F2N8O9S2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O.OS(=O)(=O)[O-]
  Pathways:Others
  Receptor:inhibits the synthesis of ergosterol; lanosterol 15 alpha-demethylase inhibitor
  Boling pt:
  Melting pt:
  Solubility:DMSO
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Kovanda LL, et al. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clin Infect Dis. 2017 May 2.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting